julho

2026

Revisado: 25 de agosto de 2026

Tratando a Biologia, Não os Canos: A Abordagem Radical e Nova para a Doença Cardíaca

Como Usar Este Artigo

Aviso médico: Este artigo é apenas para fins educativos e não constitui aconselhamento médico. Consulte sempre o seu médico para obter orientação pessoal.

Texto Fácil

Imagine que você está sentado em um pequeno consultório médico impessoal. O ar está fresco, o papel na maca de exames faz barulho sob você e seu coração bate forte contra suas costelas — não por causa de exercício, mas de medo. Seu médico olha para uma tomografia do seu tórax e diz as palavras que ninguém quer ouvir: “Você tem um entupimento.”

Nesse momento, sua mente provavelmente vai para um único lugar: a sala de cirurgia. Durante décadas, fomos ensinados a pensar em nossos corações como o encanamento de nossas casas. Se um cano entope, você contrata um encanador para desentupi-lo ou substituir a seção quebrada. No mundo da medicina, chamamos isso de “abrir os canos” usando um pequeno tubo de metal chamado stent ou realizando uma cirurgia de grande porte conhecida como ponte de safena. Nos disseram que se não corrigirmos esse entupimento específico imediatamente, um ataque cardíaco está logo ali.

Mas e se eu lhe dissesse que, para muitas pessoas, a história do “cano rompido” é um mito? E se novas pesquisas mostrassem que, para uma pessoa típica com doença cardíaca estável, a sua lista de compras pode ser mais poderosa do que os instrumentos de um cirurgião? Parece uma afirmação ousada, mas os maiores estudos médicos da história estão provando que o corpo humano se parece menos com um conjunto de canos de metal e mais com uma floresta viva e autocurativa.

Abrir os tubos nem sempre significa uma vida mais longa

A lógica antiga era simples: “Entupido é ruim, aberto é bom.” Se um médico conseguisse apenas abrir aquele vaso sanguíneo novamente, certamente o paciente viveria mais, certo? Para testar isso, os pesquisadores iniciaram dois estudos massivos chamados de Estudo COURAGE e o Estudo ISCHEMIA. Eles queriam ver se as pessoas que colocavam um stent imediatamente se saíam melhor do que aquelas que simplesmente tomavam seus remédios e mudavam seu estilo de vida.

No estudo COURAGE, que acompanhou mais de 2.000 pessoas, os resultados chocaram a comunidade médica. Após vários anos, não houve diferença no número de pessoas que morreram ou tiveram ataques cardíacos entre aquelas que colocaram um stent e aquelas que não colocaram. Quando fizeram uma nova verificação quinze anos depois, os resultados ainda eram exatamente os mesmos.

Os pesquisadores observaram que as curvas de sobrevivência — as linhas em um gráfico que mostram quem viveu e quem morreu — permaneceram “sobrepostas”. Esta é uma maneira científica de dizer que as linhas estavam perfeitamente uma em cima da outra. Quer você tenha “consertado o encanamento” ou apenas focado em hábitos saudáveis, suas chances de continuar vivo eram idênticas.

Para entender o porquê, pense em um stent como consertar um único buraco em uma rodovia que se estende por milhares de quilômetros. Se você consertar aquele trecho de trinta centímetros de asfalto na I-95, a estrada fica melhor naquele ponto específico. Mas esse remonte não impede que o resto da rodovia envelheça, rache ou desenvolva novos buracos dez milhas adiante.

O mais novo Isquemia o ensaio clínico foi ainda mais longe. Ele utilizou a melhor tecnologia moderna e descobriu a mesma coisa: para a maioria das pessoas com doença estável, recorrer imediatamente à cirurgia não ajudou a viver mais tempo. Em um acompanhamento de longo prazo chamado ISCHEMIA-EXTEND, pesquisadores viram uma estranha “compensação”. Embora a cirurgia tenha reduzido levemente o risco de morte por problemas cardíacos, isso foi equilibrado por um aumento nas mortes por outras causas. No fim das contas, o resultado foi neutro — o que significa que a cirurgia não deu ao paciente médio um “bônus” em sua expectativa de vida.

A Vantagem do “Bypass” para Casos Complexos

Agora, isso não significa que devemos jogar fora o bisturi do cirurgião. Há momentos em que “abrir os canos” é absolutamente a decisão certa. Os dados mostram que para pessoas com doença muito “emaranhada” ou complexa, a cirurgia ainda é o “Padrão-Ouro”.”

Especificamente, dois estudos chamados FREEDOM e SYNTAX mostraram que pessoas que têm tanto doença cardíaca quanto diabetes se saem muito bem com uma ponte de safena. Nestes casos, um stent é como um “conserto rápido” que pode não resistir ao alto estresse que o diabetes impõe ao corpo. Uma ponte, no entanto, é como “construir uma estrada totalmente nova” para contornar toda a área danificada.

Quem mais se beneficia da cirurgia cardíaca?

Pessoas com Diabetes: Eles tiveram significativamente menos ataques cardíacos e mortes com cirurgia de ponte de safena em comparação com os stents. No estudo FREEDOM, a taxa de mortalidade entre os diabéticos foi de cerca de 18% com uma cirurgia de ponte de safena, em comparação com 24% entre aqueles que receberam stents.
Pessoas com Muitas Barreiras: Quando a doença está “emaranhada” em muitos “tubos” diferentes ao mesmo tempo, uma ponte (bypass) oferece uma solução mais durável.
Pessoas com doença do tronco da coronária esquerda: Isto se refere a um entupimento na linha primária artéria que alimenta uma parcela massiva do coração. Como este ponto é de altíssimo risco, uma ponte de safena é frequentemente a aposta mais segura a longo prazo.

Alimento Pode Ser Remédio “Limpa-Cano”

Talvez a descoberta mais transformadora da medicina moderna seja a de que não precisamos apenas conviver com as obstruções — nós podemos realmente fazê-las sumir. Costumávamos pensar que, uma vez entupida, a artéria continuava entupida para sempre. Mas pioneiros como o Dr. Dean Ornish e o Dr. Caldwell Esselstyn provaram que podemos alcançar “redução de bloqueios”sem cirurgia alguma.

No “Lifestyle Heart Trial”, os pacientes foram convidados a adotar uma dieta estrita baseada em vegetais integrais. Isso significava comer muitos vegetais, frutas e feijões, evitando carne, laticínios e óleos adicionados. Eles também caminhavam diariamente e praticavam o controle do estresse. Os resultados foram nada menos que um milagre. No grupo que mudou seu estilo de vida, as obstruções em suas artérias realmente começaram a diminuir. Enquanto isso, o grupo que seguiu o conselho médico “padrão” viu suas obstruções piorarem.

Os dados eram impressionantes: os pacientes viram seus “ruins colesterol” diminuíram em 37%. Mais importante ainda, suas dificuldades diárias com dores no peito diminuíram em 72%.

A pesquisa encontrou uma “relação direta entre adesão e o grau de encolhimento.” Isso significa que quanto mais as pessoas seguiam o plano baseado em vegetais, mais suas artérias se abriam.

Pense em um dieta à base de plantas como “enviar uma equipe de limpeza” para todos os vasos sanguíneos do seu corpo. Ao contrário de um stent, que toca apenas em um pequeno ponto, os nutrientes dos alimentos saudáveis viajam por todo o seu sistema. Eles esfregam as paredes das suas artérias e ajudam os “canos” a se curarem de dentro para fora.

Os stents ajudam você a se sentir melhor, não apenas a viver mais

Se os stents nem sempre ajudam você a viver mais, você pode se perguntar por que ainda fazemos tantos deles. A resposta tem a ver com a “qualidade de vida”. Embora queiramos viver muito tempo, também queremos nos sentir bem enquanto estamos aqui.

Um estudo chamado FAME 2 mostrou que os stents são incrivelmente eficazes para interromper a dor no peito. Para um paciente que não consegue caminhar até a caixa de correio ou brincar com os netos porque sente dor no peito, um stent pode parecer um milagre. Ele evita retornos “de emergência” ao hospital devido a uma dor assustadora.

É vital ter uma conversa honesta com o seu médico. Você precisa perguntar: “Estou colocando este stent porque ele vai me fazer viver até os 100 anos, ou porque quero caminhar sem dor amanhã?” Na maioria dos casos estáveis, o estilo de vida e os medicamentos são o que lhe dão os anos, enquanto o stent é o que lhe dá o conforto. Ambos são importantes, mas atendem a objetivos diferentes.

Apagando o “Fogo Oculto” da Inflamação

Por muito tempo, achamos que a doença cardíaca era apenas sobre “gordura empastada” grudando nas paredes das nossas artérias. Agora sabemos que “inflamação”é o verdadeiro vilão. Pense na inflamação como um “fogo oculto” dentro do seu corpo. Quando esse fogo está queimando, ele deixa os seus vasos sanguíneos irritados, inflamados e com muito mais probabilidade de desenvolver entupimentos.

O estudo EVADE CAD analisou como uma dieta vegana afeta esse “fogo”. Eles mediram algo chamado “marcador do alarme de incêndio” (PCR-us) no sangue. Após apenas 8 semanas seguindo uma alimentação à base de vegetais, esse “marcador de inflamação” apresentou uma queda impressionante de 32%.

Comer produtos de origem animal e gorduras pesadas é como “adicionar lenha à fogueira”. Por outro lado, comer vegetais coloridos e grãos ricos em fibras é como “espirrar água nas brasas”. Ao apagar o fogo, você torna todo o seu corpo um lugar mais seguro para o seu coração bater.

O “Dream Team” (Medicamentos + Alimentos + Movimento)

O aprendizado mais importante é que você não precisa escolher entre a cura “natural” e a medicina “moderna”. Na verdade, elas funcionam melhor quando jogam no mesmo time — o “Time dos Sonhos”.”

A doença cardíaca é “sistêmica”. Ela não está em apenas um lugar; é um processo que acontece em todos os vasos, do seu cérebro até os dedos dos pés. A cirurgia é uma solução “local”, mas o estilo de vida e os medicamentos são tratamentos “sistêmicos”. Agora temos ferramentas incríveis para nos ajudar, incluindo novas injeções poderosas para baixar o colesterol e ferramentas de perda de peso como Semaglutida que demonstraram reduzir o risco cardíaco em 120 por mil em pessoas com excesso de peso.

Mesmo que você já tenha feito uma ponte de safena, seu trabalho não terminou. Os “novos tubos” usados na cirurgia (enxertos de veia) são delicados. De fato, cerca de metade deles pode se fechar em 10 anos. No entanto, quando você combina medicamentos agressivos com um estilo de vida saudável, você protege esses novos enxertos e os mantém abertos por décadas.

Os “Hábitos Essenciais” da Equipe dos Sonhos da Saúde do Coração:

Coma suas plantas: Encha seu prato com vegetais, frutas e feijões para limpar suas artérias.
Movimente seu corpo: O exercício diário mantém seus vasos sanguíneos flexíveis e fortes.
Gerencie seu peso: Usar ferramentas modernas e movimento para manter um peso saudável tira a pressão do seu coração.
Faça Parceria com a Medicina: Não tenha medo das ferramentas modernas. Seja uma pílula diária ou uma injeção semestral, essas ferramentas ajudam a manter seu colesterol na “zona segura”.”

Uma Nova Forma de Olhar para o Seu Coração

A saúde do seu coração não é um evento de “uma única vez” que acontece em uma sala de cirurgia. É uma série de pequenas e belas escolhas que você faz todas as manhãs. Embora sejamos abençoados por viver em uma época em que os cirurgiões podem realizar maravilhas técnicas, os dados são claros: o “milagre” mais sustentável acontece na sua própria cozinha e no seu próprio caminho de caminhada.

O mito do “cano quebrado” está desaparecendo. Em seu lugar, há um novo entendimento de que seu corpo é resiliente. Ele quer se curar. A remédio pode diminuir o seu risco, e a cirurgia pode ajudar com uma dor específica, mas apenas o seu estilo de vida pode tratar a “raiz” do problema em todo o seu sistema.

Ao pensar sobre a sua saúde hoje, lembre-se de que você está no banco do motorista. A cirurgia pode ser o mecânico que conserta uma peça, mas é você quem decide como o carro é dirigido e qual combustível vai para o tanque.

Faça a si mesmo a seguinte pergunta: Se a despensa da sua cozinha fosse tão poderosa quanto o bisturi de um cirurgião, como você mudaria sua lista de compras hoje? O seu coração está esperando pela sua resposta, e ele pode muito bem agradecer com uma vida inteira de batidas firmes e saudáveis.

Mergulho profundo

Resultados Clínicos, Fisiológicos e Fisiopatológicos Comparativos das Modalidades de Revascularização e da Medicina de Estilo de Vida Intensiva na Doença Arterial Coronariana Aterosclerótica

Resumo

Nas últimas duas décadas, evidências de ensaios clínicos randomizados reformulou o manejo das síndromes coronarianas estáveis (crônicas), passando de um paradigma reflexivamente intervencionista para um em que a terapia clínica direcionada por diretrizes e a modificação intensiva do estilo de vida são reconhecidas como estratégias centrais de manejo em muitos pacientes com doença estável. Esta revisão sintetiza as evidências comparativas de longo prazo em três domínios terapêuticos: (1) inicial revascularização versus terapia médica para pacientes estáveis doença arterial coronariana; (2) comparações diretas de intervenção coronária percutânea (ICP) e cirurgia de revascularização miocárdica (CRM); e (3) terapia intensiva de estilo de vida, incluindo nutrição baseada em vegetais integrais, como tratamento primário e adjuvante. Em COURAGE, Isquemia, FAME 2 e MASS II, a revascularização de rotina na doença estável não reduz mortalidade por todas as causas em relação à terapia médica ideal, embora melhore angina e reduz a revascularização urgente. Em doença multiarterial anatomicamente complexa e diabética, a cirurgia de revascularização miocárdica (CRM) confere uma vantagem de sobrevivência a longo prazo sobre a ICP. Intervenções intensivas no estilo de vida demonstram reduções na angina, marcadores inflamatórios e, em coortes selecionadas, angiographic regression of disease. Claims of lifestyle-specific reductions in in-stent restenosis or stent trombose are not supported by peer-reviewed primary data and are explicitly identified as such. Recommendations are mapped to the ACC/AHA and ESC guidance cited in this review.

1. Comparative Long-Term Clinical Outcomes of Primary Treatment Strategies

The management of stable chronic coronary disease has shifted substantially over the past two decades. Historically, a flow-limiting epicardial stenosis was viewed as an indication for mechanical revascularization to prevent infarto do miocárdio and prolong life. Modern randomized trial data have instead established broad clinical equipoise between upfront revascularization and conservative management with guideline-directed medical therapy for most patients with stable disease.

1.1 COURAGE

The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial randomized 2,287 patients with stable coronary artéria disease (CAD) and objective evidence of myocardial ischemia to percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT) or to OMT alone. At a median follow-up of 4.6 years, there was no statistically significant difference in the primary composite endpoint of all-cause mortality or nonfatal myocardial infarction (MI). [1] Enrollment occurred from 1999 to 2004 using predominantly bare-metal stents and without routine fractional flow reserve (FFR) guidance, limitations frequently cited by critics; multivessel disease was present in roughly two-thirds of participants. [1]

Extended survival surveillance of the COURAGE cohort, conducted in a subset of 1,211 patients (approximately 53%, drawn substantially from the U.S. Veterans Affairs system) over a median of 11.9 years and extending to 15 years, confirmed the persistence of this equipoise. There was no statistically significant difference in all-cause mortality, with an adjusted razão de riscos (HR) for death of 1.03 (95% CI 0.83–1.21). [2] The survival curves remained essentially superimposed throughout follow-up.

1.2 ISCHEMIA

The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial addressed the technological criticisms of COURAGE by mandating contemporary practice. ISCHEMIA randomized 5,179 patients with stable CAD and moderate-to-severe ischemia on noninvasive stress testing to an initial invasive strategy (angiography followed by PCI with drug-eluting stents [DES] or CABG, plus OMT) or an initial conservative strategy of OMT alone. [3] Over a median follow-up of 3.2 years, the primary five-component endpoint (cardiovascular death, MI, or hospitalization for unstable angina, heart failure, or resuscitated parada cardíaca) did not differ significantly between groups. [3]

1.3 ISCHEMIA-EXTEND

The observational extension, ISCHEMIA-EXTEND, followed surviving participants for a median of 5.7 years (and up to 7 years), accumulating 557 deaths—nearly double the number in the initial phase. Seven-year cumulative all-cause mortality was 12.7% in the invasive arm and 13.4% in the conservative arm (adjusted HR 1.00; 95% CI 0.85–1.18). [4]

A divergence emerged within the components of mortality. The invasive strategy was associated with a statistically significant relative reduction in cardiovascular mortality at 7 years (6.4% vs. 8.6%; adjusted HR 0.78; 95% CI 0.63–0.96), corresponding to an absolute 7-year cardiovascular mortality difference of 2.2 percentage points. This benefit was offset by a statistically significant increase in non-cardiovascular mortality in the invasive group (5.6% vs. 4.4%; adjusted HR 1.44; 95% CI 1.08–1.91), and the net effect on overall survival was neutral. [4]

Two caveats apply. These cause-specific mortality findings were obtained during observational extended follow-up collected after the randomized phase ended, so they are hypothesis-generating rather than randomized comparisons. Moreover, the biological basis for the non-cardiovascular mortality signal remains unexplained and unadjudicated. [4]

1.4 FAME 2

The Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 2 (FAME 2) trial compared FFR-guided PCI plus OMT against OMT alone in patients with stable CAD and physiologically significant stenoses (FFR ≤ 0.80); 1,220 patients were enrolled and 888 with at least one significant lesion were randomized. [5] At 5 years, the primary composite of death, MI, or urgent revascularization was significantly lower with FFR-guided PCI (13.9% vs. 27.0%; HR 0.46; 95% CI 0.34–0.63; P < 0.001), a difference driven predominantly by urgent revascularization, with no statistically significant difference in death or MI individually. [6]

Ten-year follow-up was subsequently reported (median 11.2 years) and analyzed using a win-ratio framework. The primary composite favored the PCI strategy (win ratio 1.25; 95% CI 1.01–1.56; P = 0.043), again driven overwhelmingly by reductions in urgent revascularization (component win ratio 4.57; 95% CI 2.53–8.24), while the mortality component did not favor PCI. [7] The durable signal of FAME 2 is therefore a reduction in subsequent urgent revascularization rather than a statistically significant reduction in mortality or spontaneous myocardial infarction.

1.5 MASS II

The Second Medical, Angioplasty, or Surgery Study (MASS II) randomized 611 patients with stable multivessel CAD and preserved left ventricular ejection fraction to CABG, PCI, or medical therapy alone. At 10 years, all-cause survival was statistically similar across arms: 74.9% with CABG, 75.1% with PCI, and 69.0% with medical therapy (P = 0.089). [8] Medical therapy was associated with a higher 10-year cumulative incidence of MI (20.7% vs. 10.3% with CABG and 13.3% with PCI; P < 0.010). Additional revascularization during follow-up was lowest after CABG (7.4%) and high after both PCI (41.9%) and medical therapy (39.4%; P < 0.001), reflecting the durability advantage of surgical revascularization for freedom from repeat procedures. [8]

Table 1. Primary treatment-strategy trials: revascularization versus medical therapy in stable CAD.

Trial	Cohort / comparison	Follow-up	Key findings
COURAGE	N = 2,287; stable CAD with ischemia; PCI + OMT vs. OMT	4.6 y; subset to 15 y	No significant difference in death/MI at 4.6 y. Extended (median 11.9 y): adjusted HR death 1.03 (0.83–1.21).
Isquemia	N = 5,179; moderate–severe ischemia; invasive vs. conservative	3.2 y	No significant difference in the 5-component primary endpoint.
ISCHEMIA-EXTEND	Same cohort; observational extension	5.7 y (to 7 y)	7-y all-cause mortality 12.7% vs. 13.4% (adj HR 1.00; ARD 0.7 pp). CV death 6.4% vs. 8.6% (HR 0.78; ARD 2.2 pp); non-CV death 5.6% vs. 4.4% (HR 1.44); net neutral (observational).
FAME 2	N = 1,220; FFR ≤ 0.80; FFR-guided PCI vs. OMT	5 y; 10 y (median 11.2 y)	5-y composite 13.9% vs. 27.0% (HR 0.46; ARD 13.1 pp), driven by urgent revascularization. 10-y win ratio 1.25; no significant reduction in mortality or MI.
MASS II	N = 611; multivessel, preserved EF; CABG vs. PCI vs. MT	10 y	10-y survival 74.9% / 75.1% / 69.0% (P = 0.089). MI lowest with CABG (10.3%) vs. PCI (13.3%) vs. MT (20.7%).

OMT, optimal medical therapy; MT, medical therapy; EF, ejection fraction; HR, hazard ratio (95% CI in parentheses); ARD, absolute risk difference between the compared arms (percentage points).

2. Revascularization Modalities: Head-to-Head Comparative Analyses

For patients with anatomically complex or multivessel CAD, the choice of revascularization modality is consequential. Several large randomized trials and their extended follow-ups have directly compared PCI using contemporary drug-eluting stents with CABG.

2.1 SYNTAX / SYNTAXES

The Synergy Between PCI with TAXUS and Cardiac Surgery (SYNTAX) trial randomized 1,800 patients with de novo three-vessel disease (3VD) or left main coronary artery disease (LMCAD) to PCI with first-generation paclitaxel-eluting stents or to CABG. [9] In the 10-year SYNTAX Extended Survival (SYNTAXES) study, overall all-cause mortality did not differ significantly between arms (27% with PCI vs. 24% with CABG; P = 0.092), but a significant treatment-by-anatomy interaction was present. In the 3VD cohort, CABG conferred a survival advantage (mortality 28% with PCI vs. 21% with CABG), whereas in the LMCAD cohort there was no statistically significant difference (26% with PCI vs. 28% with CABG; P for interaction = 0.019). [10]

Completeness of revascularization was a determinant of long-term survival: incomplete revascularization was more common after PCI than CABG, and patients undergoing PCI with incomplete revascularization had higher 10-year mortality than those undergoing CABG with complete revascularization. [10]

2.2 FREEDOM

The Future Revascularization Evaluation in Patients with Diabetes Mellitus (FREEDOM) trial randomized 1,900 patients with diabetes and multivessel CAD to PCI with first-generation DES or to CABG, on a background of OMT. At 5 years, the primary composite of death, MI, or acidente vascular cerebral was significantly lower with CABG (18.7% vs. 26.6%; P = 0.005), driven by reductions in all-cause mortality (10.9% vs. 16.3%) and MI (6.0% vs. 13.9%; P < 0.001). Stroke was more frequent in the CABG arm (5.2% vs. 2.4%; P = 0.03). [11]

In the FREEDOM Follow-On study, a subgroup of 943 patients was tracked for a median of 7.5 years (up to 13.2 years). CABG maintained a survival advantage, with all-cause mortality of 18.3% versus 24.3% with PCI (HR 1.36; 95% CI 1.07–1.74; P = 0.01). [12]

2.3 Left Main Disease: PRECOMBAT, EXCEL, and NOBLE

The 10-year PRECOMBAT trial randomized 600 patients with LMCAD to PCI with sirolimus-eluting stents or to CABG. There were no statistically significant differences in the primary composite of major adverse cardiac or cerebrovascular events (MACCE; 29.8% with PCI vs. 24.7% with CABG; HR 1.25; 95% CI 0.93–1.69), all-cause mortality (14.5% vs. 13.8%; HR 1.13; 95% CI 0.75–1.70), or the hard composite of death, MI, or stroke (18.2% vs. 17.5%). Ischemia-driven target-vessel revascularization was approximately twofold higher after PCI (16.1% vs. 8.0%; HR 1.98; 95% CI 1.21–3.21). [13]

The Evaluation of XIENCE versus CABG for Effectiveness of Left Main Revascularization (EXCEL) trial randomized 1,905 patients with LMCAD of low or intermediate anatomical complexity to PCI with everolimus-eluting stents or to CABG. At 5 years, the primary composite of death, stroke, or MI did not differ significantly (22.0% with PCI vs. 19.2% with CABG; P = 0.13). All-cause mortality was higher in the PCI group (13.0% vs. 9.9%; odds ratio 1.38; 95% CI 1.03–1.85), a finding that was contested because cardiovascular mortality did not differ significantly (5.0% vs. 4.5%). [14]

The EXCEL results generated substantial controversy. Much of the disagreement centered on the definition of myocardial infarction used to adjudicate events: the trial’s protocol definition emphasized post-procedural biomarcador thresholds, whereas critics argued that applying the Third Universal Definition of MI would have shifted the relative MI counts between arms and, with them, the interpretation of the primary composite. Periprocedural versus spontaneous MI weighting, and how those events map onto long-term prognosis, remained the crux of the dispute. [14], [15]

The Nordic–Baltic–British Left Main Revascularisation Study (NOBLE) randomized 1,201 patients with LMCAD to PCI with biolimus-eluting stents or to CABG. In the updated analysis, PCI was associated with worse 5-year MACCE outcomes than CABG (28.4% vs. 19.0%; HR 1.58; 95% CI 1.24–2.01; P = 0.0002), driven by higher rates of non-procedural MI (7.6% vs. 2.7%) and repeat revascularization (17.1% vs. 10.2%). All-cause mortality did not differ significantly between groups. [16], [17]

2.4 BEST

The Randomized Comparison of Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST) trial randomized 880 patients to PCI with everolimus-eluting stents or to CABG. At an extended median follow-up of 11.8 years, the primary endpoint of death, MI, or target-vessel revascularization occurred in 34.5% of the PCI group and 30.3% of the CABG group (HR 1.18; 95% CI 0.88–1.56; P = 0.26). All-cause mortality (20.5% vs. 19.9%) and stroke (5.3% vs. 5.7%) were similar, but repeat revascularization remained higher after PCI (22.6% vs. 12.7%; HR 1.92; P < 0.001), and spontaneous MI was more frequent after PCI. [18], [19]

2.5 FAME 3

The FAME 3 trial randomized 1,500 patients with three-vessel CAD to FFR-guided PCI with zotarolimus-eluting stents or to CABG. It did not meet its prespecified 1-year non-inferiority margin for the composite of death, MI, stroke, or repeat revascularization. [20] At 3 years, the composite of death, MI, or stroke did not differ significantly (12.0% with PCI vs. 9.2% with CABG; HR 1.30; 95% CI 0.98–1.83; P = 0.07), although MI (7.0% vs. 4.2%) and repeat revascularization (11.1% vs. 5.9%) were higher after PCI, while all-cause mortality was similar. [21]

Table 2. Head-to-head trials of PCI versus CABG (extended follow-up where available).

Trial	Focus (N)	Mortality (PCI vs. CABG)	Durability / safety
SYNTAXES	3VD or LMCAD (1,800)	10-y: 27% vs. 24% (P = 0.092; ARD 3 pp). 3VD: 28% vs. 21% (ARD 7 pp). LMCAD: 26% vs. 28% (NS).	Incomplete revascularization more common after PCI; associated with higher 10-y death.
FREEDOM	Diabetes + multivessel (1,900)	7.5-y: 24.3% vs. 18.3% (HR 1.36; 1.07–1.74; ARD 6.0 pp).	5-y MI 13.9% vs. 6.0%; stroke higher with CABG (5.2% vs. 2.4%).
PRECOMBAT	LMCAD (600)	10-y: 14.5% vs. 13.8% (HR 1.13; 0.75–1.70; ARD 0.7 pp).	Ischemia-driven TVR 16.1% vs. 8.0% (HR 1.98).
EXCEL	LMCAD, low/intermediate complexity (1,905)	5-y: 13.0% vs. 9.9% (OR 1.38; 1.03–1.85; ARD 3.1 pp).	Composite 22.0% vs. 19.2% (P = 0.13); revascularization 16.9% vs. 10.0%.
NOBLE	LMCAD (1,201)	All-cause mortality not significantly different.	5-y MACCE 28.4% vs. 19.0% (HR 1.58; P = 0.0002; ARD 9.4 pp); non-procedural MI 7.6% vs. 2.7%.
BEST	Multivessel (880)	11.8-y: 20.5% vs. 19.9% (P = 0.86; ARD 0.6 pp).	Primary composite 34.5% vs. 30.3% (HR 1.18; P = 0.26); repeat revascularization 22.6% vs. 12.7%.
FAME 3	3VD (1,500)	3-y all-cause mortality similar.	3-y death/MI/stroke 12.0% vs. 9.2% (HR 1.30; P = 0.07; ARD 2.8 pp); MI 7.0% vs. 4.2%.

TVR, target-vessel revascularization; OR, odds ratio; MACCE, major adverse cardiac or cerebrovascular events; NS, not significant; ARD, absolute risk difference between the compared arms (percentage points).

3. Clinical Evidence for Whole-Food Plant-Based Nutrition and Intensive Lifestyle Therapy

Whereas revascularization and pharmacotherapy address obstructive lesions and modifiable fatores de risco, intensive lifestyle therapy favorably modifies several biological pathways involved in aterosclerose. A limited but influential body of randomized and observational evidence supports its role in symptom reduction, biomarker improvement, and, in selected cohorts, angiographic stabilization or regression.

3.1 The Lifestyle Heart Trial

Ornish and colleagues conducted the Lifestyle Heart Trial, a small randomized controlled trial (48 patients; 28 in the experimental group and 20 controls) evaluating a comprehensive program comprising a 10%-fat whole-foods vegetarian diet, moderate aerobic exercise, stress management (including yoga and meditation), tabagismo cessation, and group psychosocial support, without lipid-lowering medication. [22]

Quantitative coronary angiography of 195 lesions showed that after 1 year, average percent diameter stenosis in the experimental group regressed from 40.0% to 37.8%, while the control group progressed from 42.7% to 46.1%; experimental-group Colesterol LDL fell by approximately 37%. [22] At 5 years, the divergence widened: experimental-group stenosis measured 37.3% (from a baseline of 40.7% in that analysis) versus 51.9% in controls (P = 0.001 between groups), and a direct relationship between adesão and the degree of regression was observed across both 1 and 5 years. [23] Reported anginal frequency fell by 72% in the experimental group, and the 5-year risco relativo of any cardiac event was 2.47 times higher in the control group (95% CI 1.48–4.20). Positron emission tomography at 5 years showed improved myocardial perfusion in the experimental group and worsening perfusion in controls. [23]

3.2 The Esselstyn Cohorts

Esselstyn investigated a strict 10–15%-fat whole-food dieta à base de plantas (WFPBD) excluding all animal products and added oils, combined with low-dose lipid-lowering therapy. In an initial longitudinal study of severely ill CAD patients who had collectively sustained 49 eventos cardíacos in the 8 years before enrollment, adherent patients achieved a mean colesterol total reduction from approximately 246 mg/dL to 137 mg/dL, and none experienced a recurrent cardiac event over the 12-year follow-up; serial angiography in the subset imaged demonstrated regression in several patients. [24], [25]

A subsequent uncontrolled observational study followed 198 consecutive volunteers with established doença cardiovascular who were counseled to adopt a WFPBD; because participants effectively self-selected into adherent and nonadherent groups, this design cannot establish causality. Over a mean follow-up of 3.7 years, 177 of 198 (89%) adhered. A major recurrent cardiovascular event occurred in 0.6% of adherent participants (1 of 177, a single ischemic stroke), compared with 62% of nonadherent participants (13 of 21). [26] Given the small nonadherent subgroup and the absence of randomização, these findings are hypothesis-generating rather than definitive.

3.3 EVADE CAD

To test short-term anti-inflammatory and lipid effects under randomized conditions, the Effects of a Vegan Versus the AHA-Recommended Diet in Coronary Artery Disease (EVADE CAD) trial randomized 100 patients with angiographically defined CAD on guideline-directed medical therapy to 8 weeks of a whole-food plant-based vegan diet or an AHA-recommended diet. The primary endpoint, proteína C-reativa de alta sensibilidade (PCR-us), was 32% lower with the vegan diet (95% CI for the ratio 0.47–0.94; P = 0.02). [27] Differences in LDL colesterol, glycemic markers, and body mass index between the diets did not reach statistical significance over this short interval. [27]

3.4 Intensive Cardiac Rehabilitation

Outpatient intensive cardiac rehabilitation programs that pair structured exercise with intensive nutrition and lifestyle education have been associated with improvements in functional capacity, anthropometrics, perfis lipídicos, and health-related quality of life in enrolled cohorts. Comparative effects on hard outcomes such as mortality and hospital readmission are less clearly established in the peer-reviewed literature; reported reductions in those endpoints should be interpreted cautiously pending controlled data, and program-specific marketing figures are not treated as evidence in this review.

Table 3. Representative biomarker and physiological changes with intensive lifestyle therapy.

Parameter	Baseline	Post-intervention	Source / mechanism
hs-CRP (inflamação)	1.66 mg/L (AHA-diet arm)	1.13 mg/L (vegan arm)	EVADE CAD [27]. Randomized between-group difference at 8 weeks (≈32% lower with the vegan diet), not a within-group baseline-to-post change.
Total cholesterol	~246 mg/dL	~137 mg/dL	Esselstyn cohorts [24,25]. Reduced dietary cholesterol/gordura saturada; hepatic LDL-receptor upregulation.
Colesterol LDL	Baseline	~37% reduction at 1 y	Ornish 1-year [22]. Reduced saturated-fat intake.
Diameter stenosis (QCA)	40.7%	37.3% at 5 y	Ornish 5-year [23]. Plaque stabilization/regression.
Myocardial perfusion	Regional deficits	Improved at 5 y	Ornish/Gould PET [23]. Improved endothelial-dependent vasodilation.
Angina frequency	Alto	72% reduction at 5 y	Ornish 5-year [23]. Improved vascular reactivity and perfusion.

QCA, quantitative coronary angiography; PET, positron emission tomography. Values are drawn from the cited primary studies and differ in population and design.

4. Atherosclerosis Regression: Evidence That Coronary Disease Can Be Modified

A central premise of conservative, non-procedural management is that atherosclerosis is not an inexorably progressive disease. A consistent body of angiographic and intravascular-imaging evidence shows that coronary atherosclerosis can be slowed, halted, and—to a measurable degree—regressed with intensive hipolipemiante and lifestyle modification. The magnitude of regression is generally modest in absolute terms, and its principal clinical value lies in placa stabilization and event reduction rather than in large-scale restoration of the lumen; nonetheless, the demonstration that disease is modifiable is what justifies offering an adequate trial of medical and lifestyle therapy before elective invasive procedures in stable disease. [1], [3]

4.1 Preclinical and Pharmacologic Regression

The possibility of regression was first demonstrated in experimental models. In nonhuman primates, withdrawal of dietary cholesterol and other lipid-lowering interventions produced measurable shrinkage of established atherosclerotic plaque, establishing that lesions are not permanent fixtures. [28] Subsequent primate work confirmed that diet-induced coronary and carotid lesions can regress toward normal, although they require longer to do so than lesions in other arterial segments [29], and comprehensive reviews of the animal literature concluded that regressão de placa is a reproducible phenomenon across multiple species. [30]

Early human angiographic trials then established that lipid-lowering therapy can produce regression. In the Cholesterol Lowering Atherosclerosis Study (CLAS), combined colestipol-niacin therapy reduced progression and increased regression of native coronary lesions and venous bypass grafts relative to placebo. [31] In patients with familial hypercholesterolemia, combined drug regimens that markedly lowered LDL cholesterol produced angiographic regression of coronary lesions. [32] With the advent of high-intensity statins, o ASTEROID trial used serial intravascular ultrasound to show that very high-intensity rosuvastatin—achieving a mean LDL cholesterol near 60 mg/dL—regressed coronary atheroma, reducing percent atheroma volume across the measured segments. [33] Serial quantitative angiography in lipid-lowering trials likewise documented measurable regression of coronary lesions. [34] A synthesis of the Cholesterol Lowering Atherosclerosis Study and the Monitored Atherosclerosis Regression Study (MARS) concluded that lipid lowering can halt progression and produce angiographically detectable regression, while emphasizing that the absolute changes in lumen diameter are small relative to the accompanying reduction in clinical events. [35]

The timing of pharmacologic regression has been synthesized systematically. A revisão sistemática of the time course of plaque regression found that, in studies documenting regression with statin therapy, measurable regression appeared after an average of approximately 19.7 months of treatment, consistent with a gradual process of plaque lipid depletion and stabilization rather than rapid reversal. [36] Because measurable regression often requires many months to about two years, an adequate therapeutic trial—not a brief one—is needed before concluding that medical therapy has failed to modify disease.

4.2 Lifestyle-Based Regression

Intensive lifestyle programs have likewise been associated with angiographic regression. As described in Section 3, the Lifestyle Heart Trial documented net regression of percent diameter stenosis in the intervention group at 1 and 5 years, with progression in controls [22], [23], and the Esselstyn cohorts reported regression in imaged patients adopting a whole-food plant-based diet. [24], [26]

A series of prospective Indian trials combining diet, exercise, and yoga-based stress management has added to this evidence. A randomized trial by Manchanda and colleagues found that a yoga lifestyle intervention over one year retarded coronary atherosclerosis and reduced anginal episodes in angiographically proven CAD. [37] The prospective, controlled Caring Heart Project reported regression of coronary lesions and improved myocardial perfusion with a yoga-based lifestyle program. [38] The Mount Abu Open Heart Trial, an open trial of a comprehensive low-fat vegetarian diet, moderate exercise, and Rajyoga meditation, reported that the most adherent patients regressed percent diameter stenosis by approximately 18 absolute percentage points and experienced fewer cardiac events than the least adherent. [39] These trials are limited by small size and, in most cases, open or non-randomized designs, and the benefit was strongly adherence-dependent; they are best read as supportive and hypothesis-generating rather than definitive.

4.3 Magnitude and Clinical Interpretation

Two points temper and clarify this evidence. First, the absolute magnitude of regression is modest: imaging trials typically show small reductions in percent atheroma volume or stenosis, not wholesale reopening of occluded vessels. Second, the prognostic benefit of lipid lowering and lifestyle change derives less from luminal gain than from compositional plaque stabilization—lipid depletion, reduced inflammation, and a more robust fibrous cap—which lowers the risk of ruptura de placa and clinical events. [36] At the cellular level, regression reflects reduced retention of apolipoproteína B–containing lipoproteínas in the arterial wall, efflux of cholesterol from plaque, and clearance of necrotic debris by macrophages—processes that depend on robustly and durably improving the lipoprotein profile. [40] Understood this way, regression is a marker that disease is being modified; the clinical objective of an initial medical and lifestyle strategy in stable disease is event reduction and symptom control, with regression and stabilization as the underlying mechanism. Comprehensive reviews of the regression literature reach the same conclusion: with sufficient and sustained lipid lowering, atherosclerosis can be arrested and partially regressed, though the clinical dividend is dominated by plaque stabilization rather than large luminal gain. [41]

Note: Some widely circulated reports of dramatic “reversal” are not relied upon here. The Indo-Mediterranean Diet Heart Study, for example, is the subject of a formal published expression of concern regarding the reliability of its data and is therefore excluded from this synthesis.

4.4 Combined Dietary and Pharmacologic Therapy: Adjunct or Standalone Strategy

The regression evidence falls into two streams that are most powerful in combination. Intensive dietary and lifestyle programs and lipid-lowering pharmacotherapy each reduce the atherogenic burden, but through complementary routes; the largest reductions in apolipoprotein B–containing lipoproteins—the proximate driver of plaque growth—are achieved when intensive nutrition is paired with aggressive drug therapy. The Lifestyle Heart Trial achieved regression with intensive lifestyle change alone, without lipid-lowering drugs [22], [23], whereas the Esselstyn program explicitly combined a whole-food plant-based diet with lipid-lowering medication, targeting total cholesterol below 150 mg/dL and reporting arrest and selective regression of disease [24], [26], [42]. The pharmacologic regression trials show what drug therapy contributes on its own [31], [32], [33].

Two practical points follow. First, the combined approach—whole-food plant-based nutrition together with guideline-directed lipid-lowering therapy (a high-intensity statin, with ezetimibe, bempedoic acid, or a PCSK9 inhibitor added as needed to reach apolipoprotein B targets)—is the most robust non-procedural strategy for modifying disease, and is valuable as an adjunct after revascularization. Second, in stable disease this same combination can serve as the initial standalone strategy in place of an elective procedure, with revascularization reserved for the indications noted below. Diet is not positioned here as an alternative to medication, nor medication as an alternative to diet; the evidence for arresting and regressing disease is strongest when the two are used together.

4.5 Implication: An Initial Therapeutic Trial as a Legitimate First Option in Stable Disease

Taken together with the outcome trials in Sections 1 and 2, this evidence reframes the initial management of stable coronary disease. Because routine revascularization does not reduce death or myocardial infarction in stable disease, and because intensive medical and lifestyle therapy can halt progression, stabilize plaque, and modestly regress disease, an adequate trial of guideline-directed medical therapy combined with intensive lifestyle modification is a legitimate first-line option in appropriately selected patients—not merely an adjunct layered on top of a procedure. [1], [3]

Framing this as a genuine first option has direct implications for tomada de decisão compartilhada. A patient with stable disease can be offered, and can reasonably choose, a defined period of intensive therapy with objective monitoring—symptoms, achievement of LDL cholesterol and apolipoprotein B targets, and functional capacity—with elective revascularization considered if symptoms remain refractory despite optimal therapy or if objective markers fail to improve. This sequence does not apply to acute coronary syndromes, to significant left-main or other high-risk anatomy, to diabetes with multivessel disease, or to significantly reduced left ventricular function, where revascularization improves outcomes and should not be delayed. The aim is not to withhold a needed procedure but to ensure that patients with stable disease are not moved to an elective intervention before they have had a real opportunity to modify the underlying disease.

5. Lifestyle Therapy and Pharmacologic Secondary Prevention After Revascularization

PCI and CABG are localized treatments applied to a systemic, progressive vascular disease. Implanting a stent or constructing a bypass graft does not halt the underlying atherosclerotic process, which is why secondary prevention is central to long-term outcomes after revascularization.

5.1 The Limits of the Current Evidence

A note on direct outcome claims. Specific figures sometimes circulated—for example, that a whole-food plant-based diet reduces in-stent restenosis to 2–3% (versus 10–20% in omnivores) or eliminates early stent thrombosis—are not supported by peer-reviewed primary data. The claim appears to derive from a non-indexed report describing unpublished, single-center observations; because that source provides no controlled comparative data, it should not be treated as evidence. Accordingly, this review does not assert a diet-specific restenosis or stent-thrombosis rate. What can be stated is mechanistic and indirect: dietary and lifestyle changes plausibly support post-procedural vascular health through established pathways, and aggressive lipid lowering after revascularization has documented benefits on graft patency and clinical events.

5.2 Plausible Mechanisms with Peer-Reviewed Support

Several mechanisms by which plant-predominant nutrition may favorably influence the post-revascularization vascular bed have biological support, although their translation into procedural outcomes has not been demonstrated in controlled trials:

Nitric oxide signaling. Diets rich in vegetables provide dietary nitrate and arginine substrate for nitric oxide production. Nitric oxide inhibits leukocyte and platelet adhesion, limits vascular smooth-muscle-cell proliferation, and promotes endothelial integrity—processes relevant to neointimal hyperplasia and endothelial healing; a direct link to restenosis outcomes has not been established in controlled trials.
Systemic inflammation. Plant-based dietary patterns are associated with lower hs-CRP, as shown in EVADE CAD; effects on interleukin-6 and tumor necrosis factor-α are more variable. [27]
Trimethylamine N-oxide (TMAO) pathway. Dietary carnitine, choline, and phosphatidylcholine are metabolized by gut microbiota to trimethylamine, which is oxidized hepatically to TMAO. TMAO has been associated experimentally with impaired reverse cholesterol transport, macrophage foam-cell formation, and platelet hyperreactivity; a shift toward high-fiber plant-based intake alters the microbiome and lowers TMAO, although human causal effects remain debated. [43], [44], [45]

Claims that lifestyle change preserves telomere length or protects mitochondrial function derive from small, non-randomized pilot studies conducted in men with low-risk prostate cancer, not in coronary patients, and should not be extrapolated to cardiovascular endpoints. [46], [47]

5.3 Graft Patency and Lipid Lowering After CABG

Long-term outcomes after CABG depend heavily on graft patency. The left internal mammary artery-to-left anterior descending anastomosis is durable, with 10-year patency exceeding 90%, whereas saphenous vein grafts are more vulnerable: roughly 10–20% fail within the first postoperative year and 40–50% are occluded by 10 years. [48]

The NHLBI Post Coronary Artery Bypass Graft (Post-CABG) trial demonstrated that aggressive LDL-lowering (targeting roughly 60–85 mg/dL with lovastatin, with cholestyramine as needed) reduced angiographic progression in saphenous vein grafts compared with moderate lowering: 27% of grafts progressed in the aggressive arm versus 39% in the moderate arm (P < 0.001), an approximately 31% relative reduction. [49] Longer-term clinical follow-up associated the aggressive strategy with reductions in revascularization and composite clinical events. [50]

5.4 Contemporary Pharmacologic Secondary Prevention

Beyond statins, several agents with proven cardiovascular benefit are increasingly used after revascularization, complementing rather than replacing lifestyle therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies achieve substantial additional LDL-cholesterol lowering and reduce recurrent events: evolocumab reduced major cardiovascular events in patients with established atherosclerotic disease on statin therapy [51], and alirocumab reduced events after acute coronary syndrome. [52] Inclisiran, a small interfering RNA that suppresses hepatic PCSK9 synthesis, produces durable LDL-cholesterol reductions with twice-yearly dosing. [53] Bempedoic acid, an ATP-citrate lyase inhibitor, reduced major adverse cardiovascular events in statin-intolerant patients. [54] Among glucagon-like peptide-1 receptor agonists, semaglutide reduced major adverse cardiovascular events by approximately 20% in patients with established cardiovascular disease and overweight or obesidade but without diabetes. [55]

These therapies act on lipid and cardiometabolic pathways that intensive lifestyle modification also influences. Reduction of saturated-fat intake supports the achievement of aggressive LDL cholesterol and apolipoprotein B targets, while exercise, weight management, and smoking cessation address the systemic substrate of disease in both grafted and native vessels. Contemporary secondary prevention therefore integrates pharmacotherapy with dietary and behavioral intervention, rather than treating either as a substitute for the other.

6. Subgroup Analysis and Patient-Level Risk Stratification

The relative value of revascularization versus intensive medical and lifestyle therapy depends on patient-specific anatomy and clinical characteristics. Stratification helps identify the optimal pathway.

6.1 Diabetes

In FREEDOM, patients with type 2 diabetes and multivessel disease randomized to CABG had significantly lower 5-year rates of death, MI, and stroke than those receiving PCI (18.7% vs. 26.6%; P = 0.005), consistent across insulin-dependent and non-insulin-dependent subgroups. [11] In BARI 2D, the advantage of prompt revascularization over medical therapy was concentrated in the stratum selected for CABG, where major cardiovascular events were reduced; in the PCI-selected stratum, prompt revascularization did not differ significantly from medical therapy. [56] The consistent signal is thus the superiority of CABG over PCI in diabetic multivessel disease, rather than a broad superiority of any revascularization over optimal medical therapy. Intensive lifestyle and weight-management programs can induce remission of type 2 diabetes—demonstrated, for example, by the DiRECT trial using a structured low-calorie program rather than a plant-based diet specifically—providing a rationale for combining metabolic optimization with revascularization in diabetic patients. [57]

6.2 Chronic Kidney Disease

The ISCHEMIA-CKD trial randomized 777 patients with advanced doença renal crônica (eGFR < 30 mL/min/1.73 m² or dialysis) and moderate-to-severe ischemia to an initial invasive or conservative strategy. Over a median follow-up of 2.2 years, the primary endpoint of death or nonfatal MI did not differ significantly between groups. [58] Given the elevated risk of contrast-associated kidney injury and procedural complications in this population, an initial conservative strategy with intensive medical therapy may be reasonable in many such patients, with invasive management reserved for refractory symptoms.

6.3 Left Ventricular Function

Patients with preserved ejection fraction and stable CAD do not derive a survival benefit from routine revascularization over OMT. In contrast, for ischemic cardiomiopatia with severely reduced systolic function (LVEF ≤ 35%), the STICH/STICHES program demonstrated a long-term mortality benefit with CABG by 10 years, even though the 5-year intention-to-treat result was neutral. [59], [60]

6.4 Stable Disease versus Acute Coronary Syndromes

In acute coronary syndromes (STEMI and high-risk NSTE-ACS), urgent revascularization is guideline-directed and, in appropriate settings, life-saving; intensive lifestyle therapy has no role as primary acute treatment. In stable chronic coronary syndromes, by contrast, routine revascularization does not improve survival or reduce spontaneous myocardial infarction relative to intensive medical and lifestyle therapy, making conservative management a reasonable strategy for many patients.

6.5 Anatomical Complexity and Completeness of Revascularization

Patients with low anatomical complexity (low SYNTAX score) generally do equally well with PCI or CABG, whereas those with moderate or high complexity derive a long-term survival advantage from CABG. A 10-year pooled analysis of individual patient data from multivessel and left-main trials found higher long-term mortality with PCI than CABG among patients with higher anatomical complexity. [61] For complex three-vessel disease, SYNTAXES confirmed a 10-year survival benefit with CABG. [10] The completeness of revascularization is closely tied to this difference; when complete or near-complete revascularization cannot be achieved percutaneously, CABG is favored.

6.6 Conduit Choice in CABG

Conduit strategy influences durability. Use of a radial-artery graft instead of a saphenous vein graft improved clinical outcomes in a pooled analysis of randomized trials. [62] By contrast, the Arterial Revascularization Trial did not show a statistically significant intention-to-treat survival advantage for bilateral over single internal-thoracic-artery grafting at 10 years, tempering earlier expectations for routine bilateral mammary grafting. [63]

7. Guideline Recommendations

The following items summarize how the evidence above maps onto the ACC/AHA and ESC guidance cited in this review. Class and level-of-evidence (LOE) designations are stated as published; where US and European documents differ, both are noted.

7.1 Class I (Recommended)

Healthy dietary patterns emphasizing vegetables, fruits, legumes, nuts, whole grains, and fish to reduce atherosclerotic cardiovascular disease risk (ACC/AHA Primary Prevention: Class I, LOE B-R). [64]
Exercise-based cardiac rehabilitation for secondary prevention after MI, CABG, PCI, or in stable angina, to reduce cardiovascular morbidity (secondary-prevention guidance; Class I). [65]
CABG in preference to PCI for patients with diabetes and multivessel CAD of intermediate-to-high anatomical complexity, to improve survival (ACC/AHA Revascularization: Class 1, LOE A). [65]
High-intensity statin therapy, with addition of non-statin agents as needed, after CABG or PCI. The ESC/EAS target for very-high-risk patients is LDL cholesterol < 55 mg/dL (Class I, LOE A); the 2018 AHA/ACC framework intensifies therapy at an LDL threshold of ≥ 70 mg/dL rather than specifying a < 55 mg/dL goal. [66], [67]

7.2 Class IIa (Reasonable)

Invasive functional testing (FFR or instantaneous wave-free ratio) to evaluate intermediate-severity stenoses before revascularization in chronic coronary syndromes. [65]
PCI as an alternative to CABG in selected patients with left main disease of low-to-medium anatomical complexity in whom equivalent revascularization can be achieved, to improve survival (ACC/AHA Revascularization: Class 2a, LOE B-NR). [65]

7.3 Class IIb / Class III (Limited or No Benefit)

For stable multivessel CAD with normal left ventricular function, the 2021 ACC/AHA/SCAI guideline distinguishes the two modes when the goal is to improve survival: CABG may be reasonable to improve survival (Class 2b), whereas the usefulness of PCI to improve survival is uncertain (Class 2b). Both reflect the attenuation of any survival advantage in the ISCHEMIA era. [65]
PCI performed solely to improve survival in patients with stable coronary disease, normal left ventricular function, and no left-main or other high-risk anatomic indication is not recommended (Class III). [65]

Note: A recommendation to substitute plant proteína for animal protein on the basis of hs-CRP is not part of the ACC/AHA or ESC guidance cited here and is not asserted in this review. hs-CRP appears in these guidelines as a risk-enhancing factor, not a dietary treatment target.

7.4 Current European Guidance (2024 ESC Chronic Coronary Syndromes)

The 2024 ESC Guidelines for the management of chronic coronary syndromes, endorsed by the European Association for Cardio-Thoracic Surgery, are the current European standard for stable disease and are consistent with the framework above. They reserve coronary revascularization for symptoms refractory to medical therapy or for high-risk anatomy (left-main, proximal left anterior descending, or multivessel disease), and they make optimized lifestyle and risk-factor modification together with disease-modifying medical therapy the foundation of care. For significant left-main disease at low surgical risk, CABG is recommended over medical therapy to improve survival and as the preferred mode over PCI; for severely reduced left ventricular function, the choice between revascularization and medical therapy is individualized by the Heart Team. The guideline also broadens the conception of chronic coronary syndromes to encompass angina or ischemia with non-obstructive artérias coronárias. [68]

8. Areas of Clinical Uncertainty

The ISCHEMIA-EXTEND non-cardiovascular mortality signal. The mechanism for the increase in non-cardiovascular deaths in the invasive arm (5.6% vs. 4.4%; adjusted HR 1.44) is unexplained and unadjudicated, and the finding arose during observational follow-up, precluding a definitive safety interpretation. [4]
Absence of large-scale trials of diet-induced regression. Although small randomized trials and prospective registries report angiographic stabilization or regression and low event rates, adequately powered multicenter trials evaluating a whole-food plant-based diet as a standalone primary therapy for stable CAD are lacking. [22], [23], [26]
Tissue-engineered vascular conduits. Decellularized plant scaffolds (for example, spinach-leaf cellulose) have shown proof-of-concept perfusability and endothelialization in preclinical work, but their mechanical durability under human arterial pressures is untested clinically; this remains an experimental, preclinical line of inquiry. [69]

9. Strategic Decision Synthesis

9.1 When is PCI the best primary therapy?

For ST-elevation and many high-risk non–ST-elevation acute coronary syndromes, urgent revascularization—most often PCI—is a primary, evidence-based treatment that limits myocardial necrosis and reduces mortality. In stable disease, PCI is preferred for refractory angina despite maximal medical and lifestyle therapy when anatomy is of low complexity and complete or near-complete revascularization can be achieved with few stents, and as a less-invasive alternative to CABG in selected left-main disease of low-to-medium complexity, particularly in patients at high surgical risk or advanced age.

9.2 When is CABG the best primary therapy?

CABG remains the standard for complex multivessel disease (higher SYNTAX score) where complete percutaneous revascularization is not feasible; for diabetes with multivessel CAD; for ischemic cardiomyopathy with LVEF ≤ 35%; and for complex left-main or proximal-LAD multivessel disease, where the durability of the internal-mammary-to-LAD graft supports superior long-term outcomes. [10], [11], [60]

9.3 When is intensive lifestyle plus medical therapy the best primary strategy?

Intensive lifestyle therapy combined with optimal medical therapy is an appropriate first-line strategy for stable chronic coronary syndromes without left-main disease or severely reduced LVEF, where upfront revascularization does not reduce death or MI; for single-vessel or low-complexity disease; for advanced chronic kidney disease, where revascularization does not improve survival but carries high procedural risk; and for patients with diffuse or non-bypassable disease unsuitable for mechanical revascularization. [3], [4], [58]

9.4 What does lifestyle therapy add after revascularization?

After revascularization, intensive lifestyle therapy is best understood as comprehensive secondary prevention. Its documented contributions are reduction of inflammatory markers (for example, hs-CRP), support for achieving aggressive LDL cholesterol and apolipoprotein B targets alongside pharmacotherapy, and improvement in angina and functional capacity. [27], [49] It should not be presented as producing specific reductions in in-stent restenosis or stent thrombosis, for which controlled evidence is absent.

10. Conclusion

For patients with stable (chronic) coronary disease, the evidence reviewed here supports a clear sequencing principle: an adequate trial of guideline-directed medical therapy and intensive lifestyle modification should generally precede elective invasive revascularization in appropriately selected stable patients without high-risk anatomy. Three findings converge on this conclusion. First, in stable disease, routine revascularization added to medical therapy does not reduce death or myocardial infarction relative to medical therapy alone. [1], [3], [4] Second, atherosclerosis is modifiable: intensive lipid lowering and lifestyle change can halt progression, stabilize plaque, and produce measurable regression. [33], [39] Third, because regression and stabilization often develop over many months to about two years, the therapeutic trial should be of adequate duration and intensity before medical therapy is judged to have failed. [36]

This sequencing is bounded by important exceptions. It does not apply to acute coronary syndromes, where urgent revascularization is guideline-directed and frequently life-saving; nor should it delay revascularization in patients with refractory symptoms despite optimal therapy, significant left main or complex multivessel disease, diabetes with multivessel disease, or significantly reduced left ventricular function, for whom revascularization—often CABG—improves outcomes. [11], [60]

Within those boundaries, the implication for practice and shared decision-making is straightforward. Patients with stable coronary disease deserve a genuine opportunity to modify their disease with medicines and lifestyle change—an approach that, in randomized trials, has not been associated with higher rates of death or myocardial infarction, carries no procedural risk, and addresses the systemic biology of atherosclerosis—before elective procedures are undertaken. Revascularization remains an essential tool, to be deployed when symptoms or anatomy warrant it, rather than as a reflexive first response to a stable stenosis.

Funding and Disclosures

This review was prepared by Curing Heart Disease, LLC, an independent cardiovascular health–education platform, and received no external commercial or grant funding. The author is the founder and operator of Curing Heart Disease, LLC, which produces educational content, tools, and related services in the area of cardiovascular disease prevention; readers should consider this affiliation when interpreting the review. The content reflects the peer-reviewed literature cited herein and is provided for educational purposes only. It is not medical advice; for diagnosis or treatment, consult a qualified healthcare professional.

Referências

Transparency Note: This blog post was created with assistance from AI tools. The final content has been carefully reviewed and edited by the author, who is responsible for its accuracy. The information provided is for educational purposes only and does not constitute medical advice.